Skip to content
OpenCapital
Get started

Kymera Therapeutics KYMR Proceeds from issuance of common stock relating to employee stock plans

Proceeds from issuance of common stock relating to employee stock plans at other companies

Incyte logo
IncyteINCY
——

Other financials

Income statement

See full
Revenue$34.4M+55.5%
Operating income-$84.2M-13.1%
Net income-$69.2M-5.6%
EPS (diluted)-$0.71+13.4%

Balance sheet

See full
Cash & equivalents$144.1M+60.2%
Total debt$82.2M-6.5%
Total equity$1.5B+95.8%
Total assets$1.7B+81.7%

Cash flow

See full
Operating cash flow-$88.8M-12.2%
CapEx$434.0K-7.1%
Free cash flow-$89.3M-12.1%

Valuation

See full
Market cap$7.44B+283%
Enterprise value$7.38B+280%
P/S144.5×+111×

Profitability

See full
Operating margin-697.7%+635pp
Net margin-612%+602pp
FCF margin-474%+92.4pp

Returns & leverage

See full
Return on equity-27.1%-3.7pp
Debt / equity0.1×-0.1×
Current ratio10.8×+2.3×

Where this comes from

Reported directly by Kymera Therapeutics in its filing.

Tagged under the XBRL concept us-gaap:ProceedsFromStockPlans.

The official record: Kymera Therapeutics’s 10-Q, filed April 30, 2026, on SEC EDGAR. View the filing →

Ask your AI about Kymera Therapeutics's proceeds from issuance of common stock relating to employee stock plans.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Kymera Therapeutics's proceeds from issuance of common stock relating to employee stock plans?
Kymera Therapeutics (KYMR) reported proceeds from issuance of common stock relating to employee stock plans of $19.19M in Q1 2026.
How has Kymera Therapeutics's proceeds from issuance of common stock relating to employee stock plans changed year-over-year?
Kymera Therapeutics's proceeds from issuance of common stock relating to employee stock plans increased by 3487.7% year-over-year, from $535K to $19.19M.
What is the long-term trend for Kymera Therapeutics's proceeds from issuance of common stock relating to employee stock plans?
Over 2 years (2023 to 2025), Kymera Therapeutics's proceeds from issuance of common stock relating to employee stock plans has grown at a 364.2% compound annual growth rate (CAGR), from $2.86M to $61.62M.